Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu
{"title":"Molecular prognostic factors in colorectal cancer: 5-year follow-up.","authors":"Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu","doi":"10.47162/RJME.64.1.08","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.</p>","PeriodicalId":54447,"journal":{"name":"Romanian Journal of Morphology and Embryology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/e3/RJME-64-1-65.PMC10257784.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Journal of Morphology and Embryology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47162/RJME.64.1.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.
期刊介绍：
Romanian Journal of Morphology and Embryology (Rom J Morphol Embryol) publishes studies on all aspects of normal morphology and human comparative and experimental pathology. The Journal accepts only researches that utilize modern investigation methods (studies of anatomy, pathology, cytopathology, immunohistochemistry, histochemistry, immunology, morphometry, molecular and cellular biology, electronic microscopy, etc.).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
